Doctors are not safe with some patients.

Published Date: 16 Feb 2023

Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.

Read Full News

Latest News

Bladder Issues Linger in Kids Treated for Ureter Swelling

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Mastering Evolving Evidence on Systemic Immunotherapy in the Management of BCG-Naïve, High-Risk NMIBC

Mastering Evolving Evidence on Systemic Immunotherapy in the Management of BCG-Naïve, High-Risk NMIBC

Beyond BCG Alone: Clinical Pearls for Integrating Immunotherapy Earlier in High-Risk NMIBC

Beyond BCG Alone: Clinical Pearls for Integrating Immunotherapy Earlier in High-Risk NMIBC

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Mastering Evolving Evidence on Systemic Immunotherapy in the Management of BCG-Naïve, High-Risk NMIBC

Beyond BCG Alone: Clinical Pearls for Integrating Immunotherapy Earlier in High-Risk NMIBC

News All Time

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Personalized Decision-Making for Patients With Advanced HSPC

Personalized Decision-Making for Patients With Advanced HSPC

Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety

Too Much or Too Little Opioid Pain Relief May Drive Refills After Urologic Surgery

Discharge prescription mismatch versus inpatient dose significantly increased refill rate

Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer

POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance

Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG

Low-Intensity Ultrasound Shatters Kidney Stones in 70% of SOUND Trial Patients

Non-invasive, no-anesthesia lithotripsy recently gained FDA approval

Temporary Prostatic Urethra Expander for BPH/LUTS Shows Durable Results

Study showed immediate improvement in symptoms after intentional retrieval of device at 6 months

Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer

U.S. study supports findings from a global trial using an external control arm

He Inserted a Cable in His Penis. 10 Years Later, He Needed Surgery.

Patient in his 60s eventually developed sepsis

Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse

Significantly higher risk of sedative, opioid, cocaine abuse compared with no ED diagnosis

GLP-1 Drugs Linked to Significant Boost in Testosterone Levels for Men

Weight loss likely not the only reason for improvement, researcher says

Tibial Nerve Stimulation for Overactive Bladder Tied to Better Quality of Life

But main results from sham-controlled trial still outstanding

Recommended News For You

Nuclear missile workers are contracting cancer: They blame the bases

High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.

Morning Immunotherapy Does Not Boost Lung Cancer Survival

New methods show how fast breast cancers grow and how surgery delays affect cancer staging

New clinical recommendation for local treatment of oligometastatic lung cancer.

A study outlines the need for policies that enhance cancer patients' autonomy and information.

Radiation therapy for patients with breast cancer

Recommended Articles For You

Demystifying Hypereosinophilic Syndrome: Symptoms, Diagnosis, and Treatment Options  

Precision Risk Mapping in Cancer Prevention Programs 

The Algorithmic Oncologist: A Comparative Clinical Review of AI in Predictive Cancer Planning 

Exploring the Hope of New Treatments for Rhabdomyosarcoma 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New Immune Therapy Boosts Disease Control in Prostate Cancer

2.

According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.

3.

Stem Cell Transplant Associated With Better PFS in NKTCL

4.

Liver cancer cells under pressure: Compression can spark invasion, drug resistance and altered gene activity

5.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

1.

Artificial Intelligence for Bone Marrow Cellular Ecosystem Modeling

2.

Exploring the Causes and Treatments of Bacterial Keratitis: A Comprehensive Guide

3.

Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment

4.

All You Need To Know About Partial Thromboplastin Time (PTT) Test

5.

Role of Type I Interferons and KDM1B in Driving Cancer Stemness and Therapeutic Evasion

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Expert Perspectives on Hematology

2.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

3.

Nutrition During Cancer Treatment

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

5.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot